Risk factors for infections requiring hospitalization in renal transplant recipients: A cohort study

International Journal of Infectious Diseases

Volumn 15, Issue 3, 2011, Pages

  Valdez Ortiz, Rafael ^a   Sifuentes Osornio, José ^a   Morales Buenrostro, Luis E ^a   Ayala Palma, Harold ^a   Dehesa López, Edgar ^a   Alberú, Josefina ^a   Correa Rotter, Ricardo ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Infection; Renal transplantation; Risk factors

Indexed keywords

ADULT; ARTICLE; BACTEREMIA; CANDIDA; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; GASTROENTERITIS; GRAFT RECIPIENT; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PNEUMONIA; RISK FACTOR; SURGICAL INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION;

ADULT; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MEXICO; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79952103843     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.11.004     Document Type: Article

References (54)

1. Haresnahan B.A., Johnson C.P., Bresnahan B.A., Taranto S.E., McIntosh M.J., Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000, 342:605-612.
2. Tolkoff-Rubin N.E., Rubin R.H. Opportunistic fungal and bacterial infection in the renal transplant recipient. J Am Soc Nephrol 1992, 2(12 Suppl):S264-S269.
3. Dummer J.S., Ho M. Infections in solid organ transplant recipients. Principles and practice of infectious diseases 2000, 3148-3158. Churchill Livingstone, Philadelphia, PA. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
4. Alangaden G.J., Thyagarajan R., Gruber S.A., Morawski K., Garnick J., El-Amm J.M., et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 2006, 20:401-409.
5. Pereyra F., Rubin R.H. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004, 17:357-361.
6. Kotton C.N., Fishman J.A. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005, 16:1758-1774.
7. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 1998, 338:741-751.
8. Patel R. Infections in recipients of kidney transplants. Infect Dis Clin North Am 2001, 15:1-52.
9. Snydman D.R. Infection in solid organ transplantation. Transplant Infect Dis 1999, 1:21-28.
10. Pieringer H., Biesenbach G. Risk factors for delayed kidney function and impact of delayed function on patient and graft survival in adult graft recipients. Clin Transplant 2005, 19:391-398.
11. Báez-Saldaña A.R., Pérez-Padilla J.R., Salazar-Lezama M.A. Inconsistencies between tuberculosis reporting by the Ministry of Health and the World Health Organization, Mexico, 1981-1998. Salud Pública Mex 2003, 45:78-83.
12. Dirección General de Estadística e Informática, Secretaría de Salud, México. Principales resultados de la estadística sobre mortalidad en México 1998. Salud Pública Mex 2000; 42:155-61.
13. Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003, 3:156-161.
14. Stevens G., Dias R.H., Thomas K.J., Rivera J.A., Carvalho N., Barquera S., et al. Characterizing the epidemiological transition in Mexico: national and subnational burden of diseases, injuries, and risk factors. PLoS Med 2008, 17:e125.
15. San Juan R., Aguado J.M., Lumbreras C., Díaz-Pedroche C., López-Medrano F. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007, 7:964-971. RESITRA Network, Spain.
16. Webster A.C., Woodroffe R.C., Taylor R.S., Chapman J.R., Craig J.C. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005, 331:810-821.
17. Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressant regimens. Curr Opin Infect Dis 2005, 18:342-345.
18. de Souza R.M., Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol 2008, 4:252-264.
19. Chuang P., Parikh C.R., Langane A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Transplant 2005, 19:230-235.
20. Sorto R., Irizar S.S., Delgadillo G., Alberú J., Correa-Rotter R., Morales-Buenrostro L.E. Risk factors for urinary tract infections during the first year after kidney transplantation. Transplant Proc 2010, 42:280-281.
21. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. Infectious Diseases Society of America.
22. Pazik J., Durlik M., Lewandowska D., Lewandowski Z., Tronina O., Baczkowska T., et al. Pneumonia in kidney allograft recipients. Transplant Proc 2003, 35:2202-2204.
23. Gasink L.B., Blumberg E.A. Bacterial and mycobacterial pneumonia in transplant recipients. Clin Chest Med 2005, 26:647-659.
24. Shorr A.F., Owens R.C. Guidelines and quality for community-acquired pneumonia: measures from the Joint Commission and the Centers for Medicare and Medicaid Services. Am J Health Syst Pharm 2009, 66(Suppl 4):S2-7.
25. Hernández-Hernández E., Alberú J., González-Michaca L., Bobadilla-del Valle M., Quiroz-Mejía R.A., Baizabal-Olarte R., et al. Screening for tuberculosis in the study of the living renal donor in a developing country. Transplantation 2006, 81:290-292.
26. Veroux M., Giuffrida G., Corona D., Gagliano M., Scriffignano V., Vizcarra D., et al. Infective complications in renal allograft recipients: epidemiology and outcome. Transplant Proc 2008, 40:1873-1876.
27. Silva M., Marra A.R., Pereira C.A., Medina-Pestana J.O., Camargo L.F. Bloodstream infection after kidney transplantation: epidemiology, microbiology, associated risk factors, and outcome. Transplantation 2010, 90:581-587.
28. Linares L., García-Goez J.F., Cervera C., Almela M., Sanclemente G., Cofán F., et al. Early bacteremia after solid organ transplantation. Transplant Proc 2009, 41:2262-2264.
29. Rubin R. Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant-induced gastrointestinal toxicities. Clin Transplant 2001, 15(Suppl 4):11-22.
30. Tolkoff-Rubin N.E., Rubin R.H. Recent advances in the diagnosis and management of infection in the organ transplant recipient. Semin Nephrol 2000, 20:148-163.
31. Mayorga H., Ortiz-Arroyo V., González-Michaca L., Sierra-Madero J.G., Muñoz T., Mancilla E., et al. Lack of association of CMV infection/disease with lower patient or graft survival in a high risk (D+/R-) group of kidney transplant recipients with long-term follow-up. Transplantation 2004, 78:483.
32. Alberú J., Morales-Buenrostro L.E., Correa-Rotter R., Muñoz-Trejo T., Zúñiga-Varga J., Cuéllar-González J.V., et al. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy. Rev Invest Clin 2008, 60:365-374.
33. Cuellar-González JV, Mayorga H, Venegas-Carrero R, González-Michaca L, Sierra-Madero J, Muñoz T, et al. The transient CMV antigenemia in kidney transplant recipients with intermediate risk (without antiviral prophylaxis) is a common phenomenon without association with graft dysfunction or disease. Abstract 27. Proceedings of the LIII Annual Meeting of the Mexican Institute of Nephrological Research (IMIN); 2004, p. 74.
34. Aranda-Verástegui F., Alberú J., Soto-Ramírez L.E., González-Aguirre H., Muñoz-Trejo T., Mancilla E., et al. Effectiveness of preemptive therapy with gancyclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease. Rev Invest Clin 2002, 54:198-203.
35. Barsoum R.S. Parasitic infections in organ transplantation. Exp Clin Transplant 2004, 2:258-267.
36. Ramos-Bonifaz B. Geografía y salud en México [Geography and health in Mexico]. In: Valdespino-Gómez JL, Velazco-Castrejón O, Escobar-Gutiérrez A, Del Rio-Zolezzi A, Ibáñez-Bernal S, Magos-López C, editors. Enfermedades tropicales en México [Tropical diseases in Mexico]. Mexico City, Mexico: Secretaria de Salud; 1994, p. 21-3.
37. Roxby A.C., Gottlieb G.S., Limaye A.P. Strongyloidiasis in transplant patients. Clin Infect Dis 2009, 49:1411-1423.
38. Belaunzaran-Zamudio PF, López-García N, Rolón-Montes de Oca AL, Sifuentes-Osornio J. Presentación clínica de estrongiloidosis en el INCMNSZ [Clinical presentation of strongyloidiasis at a tertiary-care center in Mexico]. XXVIII Annual Congress of the Mexican Association of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol 2004; 24:60.
39. Correa D., Talamás-Rohana P., Flisser A. Editorial: Parasitology in Mexico. Infect Genet Evol 2009, 9:1021-1022.
40. Dharnidharka V.R., Agodoa L.Y., Abbott K.C. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients-an analysis of USRDS data. Am J Transplant 2007, 7:653-661.
41. Calvet H.M., Yoshikawa T.T. Infections in diabetes. Infect Dis Clin North Am 2001, 15:407-421.
42. Bouza E., Moya J., Muñoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001, 15:335-355.
43. Klein N.C., Hiong U.C., Cunha B.A. Infections associated with steroid use. Infect Dis Clin North Am 2001, 15:423-432.
44. Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
45. Martins C., Pecoits-Filh R., Riella M.C. Nutrition for the post renal transplant recipients. Transplant Proc 2004, 38:1650-1654.
46. Jamil B., Nicholls K., Becker G.J., Walker R.G. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 1999, 68:1597-1603.
47. Meier-Kriesche H.U., Arndorfer J.A., Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002, 73:70-74.
48. Gupta R., Plantinga L.C., Fink N.E., Melamed M.L., Coresh J., Fox C.S., et al. Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA 2007, 297:1455-1464.
49. Terblanche M., Almong Y., Rosenson R., Smith T.S., Hackam D.G. Statins: panacea for sepsis?. Lancet Infect Dis 2006, 6:242-248.
50. Potena L., Frascaroli G., Grigioni F., Lazzarotto T., Gaia M., Tomasi L., et al. Hydroxymethyl-glutaryl coenzyme A reductase inhibition limits cytomegalovirus infection in human endothelial cell. Circulation 2004, 109:532-536.
51. Dalrymple L.S., Go A.S. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol 2008, 3:1487-1493.
52. Gill J.S., Abichandani R., Kausz A.T., Pereira B.J. Mortality after kidney transplant failure: the impact of non-immunologic factors. Kidney Int 2002, 62:1875-1883.
53. Briggs J.D. Causes of death after renal transplantation. Nephrol Dial Transplant 2001, 16:1545-1549.
54. Kanbay M., Turgut F., Covic A., Goldsmith D. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. J Nephrol 2009, 22:598-609.